Table S1: Composition of PolyPEPI1018 vaccine and predicted responses rates in *in silico* model population. PolyPEPI1018 comprises six 30-mer peptides by joining two 15-mers derived from seven tumor-associated antigens (TAAs) frequently expressed in mCRC.

Vaccine peptide[a]	Source protein (TAA)[b]	Core HLA class I epitopes (9mers)[c]	15mer fragments and core HLA class I epitopes (9mers)[#]	Predicted *in silico* response rate[d]	
				HLA class I PEPI	HLA class II PEPI
CRC_P1	TSP50	**P1A**	PS**TTMETQFPV**SEGK	53%	88%
	TSP50	**P1B**	SR**YRAQRFWSW**VGQA		
CRC_P2	EPCAM	**P2A**	V**RTYWIIIEL**KHKAR	57%	100%
	SURVIVIN	**P2B**	TAKKVR**RAIEQLAAM**		
CRC_P3	EPCAM	**P3A**	**YVDEKAPEF**SMQGLK	43%	95%
	MAGE-A8	**P3B**	DE**KVAELVRFL**LRKY		
CRC_P6	CAGE1	**P6A**	LAS**KMHSLLALM**VGL	58%	99%
	SURVIVIN	**P6B**	KDHRI**STFKNWPFL**E		
CRC_P7	CAGE1	**P7A**	P**KSMTMMPAL**FKENR	57%	87%
	SPAG9	**P7B**	SGA**VMSERVSGL**AGS		
CRC_P8	FBXO39	**P8A**	K**FMNPYNAVL**TKKFQ	90%	100%
	FBXO39	**P8B**	KVN**FFFERIMKY**ERL		
			≥ 1 PEPI	98 %	100 %
			≥ 2 PEPIs	91 %	100 %

[a]CRC_P1 and CRC_P2 are included in mixture#1, the remaining peptides form mixture#2 of PolyPEPI1018.
[b]Uniprot(1) IDs of the target proteins: EPCAM, P16422; SURVIVIN, O15392; TSP50, Q9UI38; FBXO39, Q8N4B4; SPAG9, O60271; CAGE1, Q8TC20; MAGE-A8, P43361
[c]30mer's two core HLA class I epitopes/hotspots are **Bold**, underlined (also used as 9mer test peptides in immunoassays).
[d]Percentage of subjects in the *in silico* model population who are able to bind one or more epitopes of the vaccine peptides with at least 3 autologous HLA alleles (Personal EPItope, PEPI).

Supplementary references

1. Consortium TU. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* 2018;**47**(D1):D506-D15 doi 10.1093/nar/gky1049 %J.